Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT

MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now. On August 6, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $7.

The analyst noted that the company reported solid results during the fiscal second quarter of 2025 and is developing its drug pipeline at a steady rate. Khurshid highlighted the company’s progress in treating idiopathic pulmonary fibrosis, nontuberculous mycobacterial lung disease, and pediatric uses of Afrezza.

Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT

A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.

The analyst acknowledged that while doubts regarding the upcoming TETON-2 study results for Tyvaso in IPF persist, the company’s current valuation remains attractive. This is mainly due to the royalties from Tyvaso DPI in pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapeutic products for endocrine and rare lung diseases.

While we acknowledge the potential of MNKD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNKD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.